Isofol presents conclusions from the in-depth analysis of the AGENT study
Gothenburg, Sweden, July 4, 2023 – Isofol Medical AB (publ) today presents the conclusions from the company's in-depth analysis of data from the Phase III study AGENT. The results from the analysis support the hypothesis that a different dose and administration regimen has the potential to improve the efficacy of the company's drug candidate arfolitixorin. Isofol has therefore decided to continue the development of arfolitixorin and is intensifying preparations for a possible start of a minor clinical study.The information in the press release is intended for investors. In preclinical